[Breaking] SK Biopharmaceuticals Acquires Exclusive Global License for Parkinson's Disease Drug Candidate... Worth Up to 430.7 Billion Won
SK Biopharmaceuticals announced that it has signed a contract to acquire an exclusive worldwide license for the 'c-Abl/LRRK2 dual inhibitor' being developed as a treatment for Parkinson's disease. The counterparty is FirstBio Therapeutics, and the contract was signed on the 17th. The contract is wo
![[Breaking] SK Biopharmaceuticals Acquires Exclusive Global License for Parkinson's Disease Drug Candidate... Worth Up to 430.7 Billion Won](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F06%2F581031%2F0c2a8f5a6d5bef88%2Foriginal.webp&w=1920&q=75)
SK Biopharmaceuticals announced that it has signed a contract to acquire an exclusive worldwide license for the 'c-Abl/LRRK2 dual inhibitor' being developed as a treatment for Parkinson's disease. The counterparty is FirstBio Therapeutics, and the contract was signed on the 17th.
The contract is worth up to 430.758 billion won, equivalent to 61% of SK Biopharmaceuticals' consolidated revenue for 2025.
◆ 2.5 Billion Won Upfront Payment... Milestones and Royalties Paid in Stages
SK Biopharmaceuticals will pay an upfront payment of 2.5 billion won within 30 business days of the contract date, with no rights of recovery.
Stage-based milestone technology fees for research, development, and commercialization amount to a maximum of 72.5 billion won, while net sales milestone technology fees reach up to 355.758 billion won (260 million USD). Running royalties will also be paid based on the net sales of the product. Milestone payments are made when conditions agreed upon by both parties are achieved. The exchange rate of 1,368.30 won per dollar, as of the board resolution date, was applied to the contract size and net sales milestone technology fees.
The contract period lasts until the expiration of material patents by country and product, or until payment obligations end.
◆ Small-Molecule Compound Inhibiting Both c-Abl and LRRK2
The technology covered by this contract is a dual inhibitor that simultaneously inhibits c-Abl and Type II LRRK2, both of which are involved in the key pathophysiology of Parkinson's disease. It is an early-stage Parkinson's disease treatment technology based on a small-molecule compound that modulates lysosomal dysfunction and alpha-synuclein pathology.
Development responsibilities are divided by stage. FirstBio Therapeutics will conduct the research to confirm the preclinical candidate (PCC), and once the PCC is confirmed, SK Biopharmaceuticals will take over subsequent development.
◆ Sublicense Revenues to Be Shared Between the Two Companies
If SK Biopharmaceuticals signs a sublicense agreement with a third party in the future, milestones and royalties under this contract will not be paid for that target. Instead, sublicense revenues received from the third party will be shared between the two companies at ratios specified in the contract, depending on the timing of the grant.
Meanwhile, this is a conditional contract, and expense recognition may vary depending on the success of clinical trials and product approval. If research or development is suspended by regulatory authorities or product approval fails, the contract may be terminated in accordance with its terms.
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.
![[Breaking] US October Retail Sales Rise 6.8% Year-on-Year, 0.2% Month-on-Month... Economic Indicators in Focus After CPI and PPI](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F11%2F627311%2Fa2376e0512277714%2Fvariants%2Fhero.webp&w=1920&q=75)
![[Breaking] Cyberattack via Optimizely Exposes 178 Global Organizations... CNN, BBC, HSBC, and Ledger Also Affected](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F11%2F627874%2Ffc472b72a2596aa1%2Fvariants%2Fhero.webp&w=1920&q=75)

